On Thursday, Shares of Tesla Motors, Inc. (NASDAQ:TSLA), inclined 4.04% to $280.02.
Tesla Motors, declared 11,507 Model S deliveries for Q2 2015. This was a new company record for the most cars delivered in a quarter and represents an approximate 52% enhance over Q2 last year.
There may be small changes to this delivery count (usually well under 1%), as Tesla only counts a delivery if it is transferred to the end customer and all paperwork is correct.
Also, this is only one measure of our financial performance and should not be relied on as an indicator of our quarterly financial results, which depend on a variety of factors, counting the cost of sales, foreign exchange movements and mix of directly leased vehicles.
Tesla Motors, Inc. designs, develops, manufactures, and sells electric vehicles, electric vehicle powertrain components, and stationary energy storage systems in the United States, China, Norway, and internationally. It also provides development services to develop electric vehicle powertrain components and systems for other automotive manufacturers.
Shares of Provectus Biopharmaceuticals, Inc. (NYSEMKT:PVCT), inclined 5.66% to $0.56, during its last trading session.
Provectus Biopharmaceuticals, declared that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented on July 3, 2015 at the 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015) in Osaka, Japan.
The presenter was Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke’s Cancer Center in Bethlehem, Pennsylvania, and professor of medicine at Temple University School of Medicine in Philadelphia, Pennsylvania. He serves as a principal investigator of the phase 1 clinical trial that produced the data presented, and is the lead investigator for the phase 3 clinical trial of PV-10 as an investigational treatment for melanoma which recently began. The poster presentation was titled “Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver.”
Based on the data presented, the researchers concluded that preliminary efficacy in treatment of liver tumors with PV-10, a 10% solution of rose Bengal, was observed with acceptable tolerability. The study is ongoing at three study centers with two expansion cohorts to further assess safety and response in HCC and other cancers metastatic to the liver.
Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its product line comprises PV-10, which has accomplished Phase II study for metastatic melanoma; accomplished a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, in addition to initiated a Phase I feasibility study to detect immune cell infiltration into melanomas.
Finally, Crown Castle International Corp. (NYSE:CCI), ended its last trade with 0.05% gain, and closed at $81.11.
Crown Castle International Corp., declared that the quarterly dividend on its 4.50% Mandatory Convertible Preferred Stock will be paid on August 3, 2015 to holders of record on July 15, 2015. The dividend will be paid in cash at a rate of $1.125 per share of Preferred Stock.
Crown Castle International Corp., together with its auxiliaries, owns, operates, and leases shared wireless infrastructure in the United States and Australia. The company provides towers and other structures, such as rooftops; and distributed antenna systems, a type of small cell network (small cells).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
